93 related articles for article (PubMed ID: 7967433)
1. [Thrombosis in children with acute lymphoblastic leukemia treated with the COALL protocol].
Eckhof-Donovan S; Schwamborn D; Körholz D; Michelmann I; von Kries R; Nürnberger W; Göbel U
Klin Padiatr; 1994; 206(4):327-30. PubMed ID: 7967433
[TBL] [Abstract][Full Text] [Related]
2. Low rate of severe venous thromboses in children with ALL treatment according to COALL-92 and -97 protocol.
Mauz-Körholz C; Nürnberger W; Irsfeld H; Körholz D; Göbel U
Klin Padiatr; 1999; 211(4):215-7. PubMed ID: 10472553
[TBL] [Abstract][Full Text] [Related]
3. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
Mauz-Körholz C; Junker R; Göbel U; Nowak-Göttl U
Thromb Haemost; 2000 Jun; 83(6):840-3. PubMed ID: 10896235
[TBL] [Abstract][Full Text] [Related]
4. Coagulation and fibrinolysis in children with acute lymphoblastic leukaemia treated according to the COALL-05-92-protocol.
Kirschke R; Nürnberger W; Eckhof-Donovan S; Nürnberger I; Göbel U
Klin Padiatr; 1998; 210(4):285-90. PubMed ID: 9743967
[TBL] [Abstract][Full Text] [Related]
5. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
[TBL] [Abstract][Full Text] [Related]
6. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
7. Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol.
Sutor AH; Mall V; Thomas KB
Klin Padiatr; 1999; 211(4):201-4. PubMed ID: 10472550
[TBL] [Abstract][Full Text] [Related]
8. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
9. Thrombosis and acute lymphoblastic leukaemia.
Payne JH; Vora AJ
Br J Haematol; 2007 Aug; 138(4):430-45. PubMed ID: 17608766
[TBL] [Abstract][Full Text] [Related]
10. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Ruud E; Holmstrøm H; de Lange C; Natvig S; Albertsen BK; Wesenberg F
Pediatr Hematol Oncol; 2006; 23(3):207-16. PubMed ID: 16517537
[TBL] [Abstract][Full Text] [Related]
11. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
[TBL] [Abstract][Full Text] [Related]
12. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
13. [Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols].
Sutor AH; Niemeyer C; Sauter S; Witt I; Kaufmehl K; Rombach A; Brandis M; Riehm H
Klin Padiatr; 1992; 204(4):264-73. PubMed ID: 1518263
[TBL] [Abstract][Full Text] [Related]
14. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Appel IM; Hop WC; Pieters R
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):139-46. PubMed ID: 16479196
[TBL] [Abstract][Full Text] [Related]
15. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
16. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
Appel IM; Hop WC; van Kessel-Bakvis C; Stigter R; Pieters R
Thromb Haemost; 2008 Aug; 100(2):330-7. PubMed ID: 18690355
[TBL] [Abstract][Full Text] [Related]
17. Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report.
Korte W; Feldges A; Baumgartner C; Ullmann S; Niederer V; Schmid L
Klin Padiatr; 1994; 206(4):331-3. PubMed ID: 7967434
[TBL] [Abstract][Full Text] [Related]
18. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic complications during induction chemotherapy of acute childhood lymphoblastic leukemia.
Kankirawatana S; Veerakul G; Sanpakit K; Tanphaichitr VS; Akkabutr P; Suwantol L; Mahasandana C
J Med Assoc Thai; 2002 Aug; 85 Suppl 2():S549-57. PubMed ID: 12403231
[TBL] [Abstract][Full Text] [Related]
20. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
